Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Amgen |
---|---|
Information provided by: | Amgen |
ClinicalTrials.gov Identifier: | NCT00102830 |
The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.
Condition | Intervention | Phase |
---|---|---|
Tumors |
Drug: AMG 386 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of AMG 386 in Adult Patients With Advanced Solid Tumors |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: - Have evaluable disease - Must be able to undergo MRI evaluation:
Responsible Party: | Amgen Inc. ( Global Development Leader ) |
Study ID Numbers: | 20040169 |
Study First Received: | February 3, 2005 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00102830 |
Health Authority: | United States: Food and Drug Administration |
Solid Tumor Metastatic Cancer Advanced Solid Tumors |
Neoplasm Metastasis |